Bioventus Inc. reported earnings results for the first quarter ended March 30, 2024. For the first quarter, the company reported sales was USD 129.46 million compared to USD 119.06 million a year ago. Net loss was USD 4.57 million compared to USD 139.15 million a year ago.

Basic loss per share from continuing operations was USD 0.07 compared to USD 1.28 a year ago. Basic loss per share was USD 0.07 compared to USD 2.24 a year ago.